v3.25.4
Financial Assets and Liabilities - Additional Information (Detail)
€ / shares in Units, $ / shares in Units, € in Millions
1 Months Ended 12 Months Ended
Sep. 03, 2024
USD ($)
Multiple
Sep. 30, 2024
EUR (€)
XBB
Sep. 30, 2024
USD ($)
XBB
Sep. 30, 2023
EUR (€)
XBB
Multiple
Sep. 30, 2023
USD ($)
XBB
Multiple
Mar. 31, 2022
EUR (€)
Mar. 31, 2022
USD ($)
Dec. 31, 2025
EUR (€)
Days
€ / shares
Dec. 31, 2025
USD ($)
$ / shares
Dec. 31, 2024
EUR (€)
€ / shares
Disclosure of detailed information about financial instruments [line items]                    
Carrying amount of royalty funding liabilities               € 290.9    
Carrying amount of royalty funding liabilities               290.9   € 305.4
Fair value of royalty funding liabilities               € 296.9    
Share price | € / shares               € 48.9   € 49.6
Royalty Pharma United States Yorvipath [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Funding received in exchange of royalty payments | $     $ 150,000,000              
Net proceeds after deduting offering expenses   € 134.2 $ 148,200,000              
Funding received in exchange of royalty payments | $ $ 150,000,000                  
Net revenue from sales interest payment in percentage in exchange for funding 3.00%                  
Royalty payment ending period Dec. 31, 2029                  
Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount | XBB   2 2              
Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount | XBB   1.65 1.65 1.65 1.65          
Royalty Pharma United States Skytrofa [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Funding received in exchange of royalty payments | $         $ 150,000,000          
Net proceeds after deduting offering expenses       € 136.3 146,300,000          
Funding received in exchange of royalty payments | $         $ 150,000,000          
Net revenue from sales interest payment in percentage in exchange for funding       9.15% 9.15%          
Royalty payment ending period       Dec. 31, 2031 Dec. 31, 2031          
Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount | XBB       1.925 1.925          
Derivatives [member] | Historical volatility for shares, measurement input [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Percentage of reasonably possible increase in unobservable input, liabilities               10.00% 10.00%  
Derivatives [member] | Share Price Measurement Input [Member]                    
Disclosure of detailed information about financial instruments [line items]                    
Percentage of reasonably possible increase in unobservable input, liabilities               10.00% 10.00%  
Increase decrease in derivative financial liabilities fair value               € 50.8    
Foreign Currency Conversion Option [Member]                    
Disclosure of detailed information about financial instruments [line items]                    
Increase decrease in derivative financial liabilities fair value               € 13.2    
Bottom of range [member] | Royalty Pharma United States Yorvipath [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Multiple of the purchase price were royalty payment will cease | Multiple 1.65                  
Bottom of range [member] | Royalty Pharma United States Skytrofa [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Multiple of the purchase price were royalty payment will cease | Multiple       1.65 1.65          
Top of range [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Optional Lease Extension Period               10 years    
Top of range [member] | Royalty Pharma United States Yorvipath [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Multiple of the purchase price were royalty payment will cease | Multiple 2                  
Top of range [member] | Royalty Pharma United States Skytrofa [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Multiple of the purchase price were royalty payment will cease | Multiple       1.925 1.925          
American depository shares [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Conversion price per share | $ / shares                 $ 166.34  
Convertible Senior Notes [Member]                    
Disclosure of detailed information about financial instruments [line items]                    
Borrowings, maturity           April 1, 2028 April 1, 2028 April 2028    
Principal amount | $             $ 575,000,000      
Proceeds From Issuance Of Notes           € 503.3 $ 557,900,000      
Conversion rate per note | $ / shares                 $ 6.0118  
Borrowings redemption period               April 7, 2025    
Borrowings condition for redemption               but only if the last reported sale price per ADS exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.    
Borrowings threshold percentage of sale price per share for redemption               130.00%    
Borrowings threshold trading days for redemption | Days               20    
Borrowings threshold consecutive trading days for redemption | Days               30    
Carrying amount of convertible notes               € 429.4    
Fair value of convertible notes               € 426.4    
Convertible Senior Notes [Member] | American depository shares [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Principal amount | $                 $ 1,000  
Convertible Senior Notes [Member] | Fixed interest rate [member]                    
Disclosure of detailed information about financial instruments [line items]                    
Borrowings, interest rate             2.25% 2.25% 2.25%